TG Therapeutics (TGTX)
NASDAQ:TGTX
Want to see TGTX full AI Analyst Report?
TGTX Stock Chart & Stats
$35.33
$0.31(1.11%)
At close: 4:00 PM EST
$35.33
$0.31(1.11%)
Day’s Range― - ―
52-Week Range$25.28 - $44.65
Previous CloseN/A
Volume723.16K
Average Volume (3M)2.02M
Market Cap
$6.14B
Enterprise Value$6.12B
Total Cash (Recent Filing)$514.43M
Total Debt (Recent Filing)$753.56M
Price to Earnings (P/E)12.7
Beta0.69
Next Earnings
Aug 10, 2026EPS Estimate
0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.18
Shares Outstanding153,083,570
10 Day Avg. Volume1,356,546
30 Day Avg. Volume2,022,647
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)6.64
Price to Sales (P/S)6.98
P/FCF Ratio-172.18
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue8.74
Enterprise Value/Gross Profit10.52
Enterprise Value/Ebitda39.01
Forecast
1Y Price Target
$46.60Price Target Upside31.90% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)1.29
Revenue Forecast (FY)$935.26M
Bulls Say, Bears Say
Bulls Say
Commercial Momentum & Patient AdoptionSustained multi-quarter uptake, 25k+ prescriptions and 63% U.S. YoY growth indicate durable market acceptance and physician adoption for BRIUMVI. This strengthens a recurring revenue base, supports scaling of commercial operations, and improves prospects for lifecycle extensions over the medium term.
High Product-level ProfitabilityExceptionally high gross margins and recent net income inflection suggest product-level economics that can absorb price or mix volatility. Over months, strong margins support reinvestment in R&D/commercial expansion and reduce reliance on external financing if cash conversion improves.
Strong Liquidity And Disciplined Capital AllocationA large cash balance and active buybacks provide financial flexibility to fund commercialization, subcutaneous manufacturing buildout, and trials without immediate dilution. Disciplined repurchases also signal management confidence and give optionality for strategic investments over the next several quarters.
Bears Say
Negative Operating And Free Cash FlowPersistent negative operating and free cash flow despite GAAP profits indicates earnings are not fully converting to cash, raising questions about working-capital dynamics or non-cash accounting items. This reduces cash quality and could pressure funding needs if negative cash flow persists.
High Gross-to-net/rebate PressureA structural gross-to-net around 65% materially reduces realized revenues and resilient margins versus reported top-line. Persistent rebate pressure from payors compresses net cash receipts and can limit the long-term revenue conversion from unit demand, making revenue growth less profitable.
Clinical, Regulatory And Competitive Execution RiskKey expansion plans (single‑infusion ENHANCE benefits, subcutaneous launch) hinge on positive trial/readout and regulatory steps plus device bridging. Execution risk and approval timing, together with established CD20 rivals and new modalities, create multi-quarter uncertainty for market-share expansion and long-term growth.
TG Therapeutics News
TGTX FAQ
What was TG Therapeutics’s price range in the past 12 months?
TG Therapeutics lowest stock price was $25.28 and its highest was $44.65 in the past 12 months.
What is TG Therapeutics’s market cap?
TG Therapeutics’s market cap is $6.14B.
When is TG Therapeutics’s upcoming earnings report date?
TG Therapeutics’s upcoming earnings report date is Aug 10, 2026 which is in 66 days.
How were TG Therapeutics’s earnings last quarter?
TG Therapeutics released its earnings results on May 06, 2026. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.275 by -$0.155.
Is TG Therapeutics overvalued?
According to Wall Street analysts TG Therapeutics’s price is currently Undervalued.
Does TG Therapeutics pay dividends?
TG Therapeutics does not currently pay dividends.
What is TG Therapeutics’s EPS estimate?
TG Therapeutics’s EPS estimate is 0.36.
How many shares outstanding does TG Therapeutics have?
TG Therapeutics has 153,083,570 shares outstanding.
What happened to TG Therapeutics’s price movement after its last earnings report?
TG Therapeutics reported an EPS of $0.12 in its last earnings report, missing expectations of $0.275. Following the earnings report the stock price went up 16.26%.
Which hedge fund is a major shareholder of TG Therapeutics?
Currently, no hedge funds are holding shares in TGTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TG Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$46.60 (31.90% Upside)
$46.60 (31.90% Upside)
Blogger Sentiment
Bullish
TGTX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 536.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.0%
Last 30 Days ▲ 4.8%
Last 30 Days ▲ 4.8%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
9.51%
12-Months-Change
Fundamentals
Return on Equity
87.36%
Trailing 12-Months
Asset Growth
132.81%
Trailing 12-Months
Company Description
TG Therapeutics
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
TGTX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong, tangible commercial momentum: record Q1 revenue, 63% YoY U.S. growth, rising patient counts (25,000+), improved profitability, a robust cash position and aggressive share buybacks. Management also highlighted multiple near‑term clinical catalysts (ENHANCE, subcutaneous readouts) and longer‑term expansion opportunities (subcutaneous formulation, additional indications). Offsetting this optimism are near‑term expense increases (including ~$100M subcutaneous spend), a one‑time refinancing charge, notable gross‑to‑net/rebate pressure (~65% guidance), and clinical/regulatory timing and outcome risks for key lifecycle programs and the azer‑cel program. Overall, the positives (strong revenue beats, guidance raises, cash and buybacks, lifecycle catalysts, and supportive long‑term data) materially outweigh the listed challenges, though execution and trial outcomes remain critical to sustaining the trajectory.View all TGTX earnings summariesTGTX Stock 12 Month Forecast
Average Price Target
$46.60
▲(31.90% Upside)
Technical Analysis
Ionis Pharmaceuticals
―
Jazz Pharmaceuticals
―
Axsome Therapeutics
―
Rhythm Pharmaceuticals
―
Nuvalent
―
Ownership Overview
7.54% Insiders
17.98% Mutual Funds
12.56% Other Institutional Investors
37.25% Public Companies and
Individual Investors